Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
The Journal of Biological Chemistry|December 13, 2002
Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancerPaul J Adam, Robert Boyd, Kerry L Tyson, et al.
Molecular Cancer Therapeutics|October 15, 2011
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathwayJeffrey J Wallin, Kyle A Edgar, Jane Guan, et al.
Cancer Research|June 19, 2007
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinasesFlorence I Raynaud, Suzanne Eccles, Paul A Clarke, et al.
Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.
Open Forum Infectious Diseases|September 4, 2023
The Penn Medicine COVID-19 Therapeutics Committee-Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health EmergencyGeorge L Anesi, Kathleen Degnan, Lauren Dutcher, et al.
Cancer Research|April 19, 2023
BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor GrowthSrinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, et al.
Science Advances|August 22, 2020
Development of a potent Zika virus vaccine using self-amplifying messenger RNAKate Luisi, Kaitlyn M Morabito, Katherine E Burgomaster, et al.
Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancerAdrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.
Pageof 10